United Therapeutics Corp (UTHR) Stock
Fundamentals
Latest news
About United Therapeutics Corp
United Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and innovation, the power of our brands, our entrepreneurial culture and our bioinformatics leadership. We also believe that our determination to be responsible citizens - having a positive impact on patients, the environment and society - will sustain our success in the long term. Through our wholly-owned subsidiary, Lung Biotechnology PBC, we are focused on addressing the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply. Lung Biotechnology is the first public benefit corporation subsidiary of a public biotechnology or pharmaceutical company.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D. | Founder, Chairman & CEO | 1955 |
| Mr. Michael I. Benkowitz | President & COO | 1972 |
| Mr. James C. Edgemond | CFO & Treasurer | 1968 |
| Mr. Paul A. Mahon J.D. | Executive VP, General Counsel & Corporate Secretary | 1964 |
| Harrison Silvers | Manager of Investor Relations | — |
| Ms. Holly Hobson | Associate Vice President of Human Resources | — |
| Mr. Patrick Poisson | Executive Vice President of Strategic Development | 1968 |
| Dr. Leigh Peterson | Executive Vice President of Product Development & Xenotransplantation | — |
| Mr. Gil Golden | Senior VP & Chief Medical Officer | — |



